251 related articles for article (PubMed ID: 11745416)
21. Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone.
Kawa S; Nikaido T; Unno H; Usuda N; Nakayama K; Kiyosawa K
Pancreas; 2002 Jan; 24(1):1-7. PubMed ID: 11741176
[TBL] [Abstract][Full Text] [Related]
22. Down-regulation of peroxisome proliferator-activated receptor gamma in human cervical carcinoma.
Jung TI; Baek WK; Suh SI; Jang BC; Song DK; Bae JH; Kwon KY; Bae JH; Cha SD; Bae I; Cho CH
Gynecol Oncol; 2005 May; 97(2):365-73. PubMed ID: 15863131
[TBL] [Abstract][Full Text] [Related]
23. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
[TBL] [Abstract][Full Text] [Related]
24. PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway.
Han C; Demetris AJ; Michalopoulos GK; Zhan Q; Shelhamer JH; Wu T
Hepatology; 2003 Jul; 38(1):167-77. PubMed ID: 12829999
[TBL] [Abstract][Full Text] [Related]
25. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells.
Ohta K; Endo T; Haraguchi K; Hershman JM; Onaya T
J Clin Endocrinol Metab; 2001 May; 86(5):2170-7. PubMed ID: 11344222
[TBL] [Abstract][Full Text] [Related]
26. Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines.
Bae MA; Rhee H; Song BJ
Toxicol Lett; 2003 Mar; 139(1):67-75. PubMed ID: 12595159
[TBL] [Abstract][Full Text] [Related]
27. A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation.
Burris TP; Pelton PD; Zhou L; Osborne MC; Cryan E; Demarest KT
Mol Endocrinol; 1999 Mar; 13(3):410-7. PubMed ID: 10076998
[TBL] [Abstract][Full Text] [Related]
28. Role of PPARgamma in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis.
Morrison RF; Farmer SR
J Biol Chem; 1999 Jun; 274(24):17088-97. PubMed ID: 10358062
[TBL] [Abstract][Full Text] [Related]
29. A non-thiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth.
Bruemmer D; Berger JP; Liu J; Kintscher U; Wakino S; Fleck E; Moller DE; Law RE
Eur J Pharmacol; 2003 Apr; 466(3):225-34. PubMed ID: 12694805
[TBL] [Abstract][Full Text] [Related]
30. Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells.
Yoshida K; Tanabe K; Fujii D; Oue N; Yasui W; Toge T
Anticancer Res; 2003; 23(1A):267-73. PubMed ID: 12680223
[TBL] [Abstract][Full Text] [Related]
31. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice.
Osawa E; Nakajima A; Wada K; Ishimine S; Fujisawa N; Kawamori T; Matsuhashi N; Kadowaki T; Ochiai M; Sekihara H; Nakagama H
Gastroenterology; 2003 Feb; 124(2):361-7. PubMed ID: 12557142
[TBL] [Abstract][Full Text] [Related]
32. The ligands of peroxisome proliferator-activated receptor (PPAR) gamma inhibit growth of human esophageal carcinoma cells through induction of apoptosis and cell cycle arrest.
Fujii D; Yoshida K; Tanabe K; Hihara J; Toge T
Anticancer Res; 2004; 24(3a):1409-16. PubMed ID: 15274302
[TBL] [Abstract][Full Text] [Related]
33. Ligands of peroxisome proliferator-activated receptor-gamma induce apoptosis in AR42J cells.
Masamune A; Satoh K; Sakai Y; Yoshida M; Satoh A; Shimosegawa T
Pancreas; 2002 Mar; 24(2):130-8. PubMed ID: 11854617
[TBL] [Abstract][Full Text] [Related]
34. RWJ-241947 (MCC-555), a unique peroxisome proliferator-activated receptor-gamma ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/ X-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by arsenic trioxide.
Kumagai T; Ikezoe T; Gui D; O'Kelly J; Tong XJ; Cohen FJ; Said JW; Koeffler HP
Clin Cancer Res; 2004 Feb; 10(4):1508-20. PubMed ID: 14977855
[TBL] [Abstract][Full Text] [Related]
35. Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells.
Nakashiro KI; Hayashi Y; Kita A; Tamatani T; Chlenski A; Usuda N; Hattori K; Reddy JK; Oyasu R
Am J Pathol; 2001 Aug; 159(2):591-7. PubMed ID: 11485917
[TBL] [Abstract][Full Text] [Related]
36. Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells.
Kitamura S; Miyazaki Y; Shinomura Y; Kondo S; Kanayama S; Matsuzawa Y
Jpn J Cancer Res; 1999 Jan; 90(1):75-80. PubMed ID: 10076568
[TBL] [Abstract][Full Text] [Related]
37. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.
Mueller E; Smith M; Sarraf P; Kroll T; Aiyer A; Kaufman DS; Oh W; Demetri G; Figg WD; Zhou XP; Eng C; Spiegelman BM; Kantoff PW
Proc Natl Acad Sci U S A; 2000 Sep; 97(20):10990-5. PubMed ID: 10984506
[TBL] [Abstract][Full Text] [Related]
38. Troglitazone suppresses cell growth of KU812 cells independently of PPARgamma.
Abe A; Kiriyama Y; Hirano M; Miura T; Kamiya H; Harashima H; Tokumitsu Y
Eur J Pharmacol; 2002 Feb; 436(1-2):7-13. PubMed ID: 11834241
[TBL] [Abstract][Full Text] [Related]
39. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand.
Yu HN; Lee YR; Noh EM; Lee KS; Kim JS; Song EK; Han MK; Lee YC; Kwon KB; Lee SJ; Youn HJ; Jung SH
Cell Biol Int; 2008 Aug; 32(8):906-12. PubMed ID: 18474441
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
Patel V; Lahusen T; Leethanakul C; Igishi T; Kremer M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS; Senderowicz AM
Clin Cancer Res; 2002 Nov; 8(11):3549-60. PubMed ID: 12429646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
